Title: The Effect of Nafamostat Mesilate Infusion after ERCP for Post-ERCP Pancreatitis
Version: 1 Date: 28 Feb 2022
Reviewer:  Jorge Canena
Reviewer's report:
Dear Authors
An interesting insight on the use of nafamost mesylate
Some suggestions for revision
1-In study design please clarify that there is a control group and also clarify how it was created.
Please add clarification how the is a big difference in the number of patients in each group.
2-I do suggest that in therapeutic group the authors analyze the number of patients with one risk
factor, two risk factors, etc for each group. After doing that find the mean and standard deviation
of the number of risk factors for each group and then find out if that is statistically significant and
this is important to see if the groups are comparable. I do understand the process of matching,
but it would be interesting to see the result of what I propose
3-Please provide a multivatiate analysis for severe PEP to see if nafamost is an independent
protective factor. The multivariate analysis of risk factors for PEP should be delected as it is
of no use
4- In the discussion please be more specific in showing that a severe pancreatitis was 5 in one
group and 6 in other and if despite statistical significance this is not important
5-suggest a randomized trial in proposed studies
Title: The Effect of Nafamostat Mesilate Infusion after ERCP for Post-ERCP Pancreatitis
Version: 1 Date: 28 Feb 2022
Reviewer:  Jorge Canena
Reviewer's report:
Dear Authors
An interesting insight on the use of nafamost mesylate
Some suggestions for revision
1-In study design please clarify that there is a control group and also clarify how it was created.
Please add clarification how the is a big difference in the number of patients in each group.
2-I do suggest that in therapeutic group the authors analyze the number of patients with one risk
factor, two risk factors, etc for each group. After doing that find the mean and standard deviation
of the number of risk factors for each group and then find out if that is statistically significant and
this is important to see if the groups are comparable. I do understand the process of matching,
but it would be interesting to see the result of what I propose
3-Please provide a multivatiate analysis for severe PEP to see if nafamost is an independent
protective factor. The multivariate analysis of risk factors for PEP should be delected as it is
of no use
4- In the discussion please be more specific in showing that a severe pancreatitis was 5 in one
group and 6 in other and if despite statistical significance this is not important
5-suggest a randomized trial in proposed studies
Please review this paper.
user
Title: The Effect of Nafamostat Mesilate Infusion after ERCP for Post-ERCP Pancreatitis
Version: 1 Date: 28 Feb 2022
Reviewer:  Jorge Canena
Reviewer's report:
Dear Authors
An interesting insight on the use of nafamost mesylate
Some suggestions for revision
1-In study design please clarify that there is a control group and also clarify how it was created.
Please add clarification how the is a big difference in the number of patients in each group.
2-I do suggest that in therapeutic group the authors analyze the number of patients with one risk
factor, two risk factors, etc for each group. After doing that find the mean and standard deviation
of the number of risk factors for each group and then find out if that is statistically significant and
this is important to see if the groups are comparable. I do understand the process of matching,
but it would be interesting to see the result of what I propose
3-Please provide a multivatiate analysis for severe PEP to see if nafamost is an independent
protective factor. The multivariate analysis of risk factors for PEP should be delected as it is
of no use
4- In the discussion please be more specific in showing that a severe pancreatitis was 5 in one
group and 6 in other and if despite statistical significance this is not important
5-suggest a randomized trial in proposed studies
assistant